Use of BI853520 in cancer treatment
US12059421B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 13, 2023 |
| Grant date | Aug 13, 2024 |
| Priority date | — |
| Expiry date | Jul 13, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.